Female breast cancer treatment and survival in South Australia: Results from linked health data.

Li, M; Roder, D; D'Onise, K; Walters, D; Farshid, G; Buckley, E; Karapetis, C; Joshi, R; Price, T; Townsend, A; Miller, C; Currow, D; Powell, K; Buranyi-Trevarton, D; Olver, I

Female breast cancer treatment and survival in South Australia: Results from linked health data.

Li, M Roder, D D'Onise, K Walters, D Farshid, G Buckley, E Karapetis, C Joshi, R Price, T Townsend, A Miller, C Currow, D

Powell, K Buranyi-Trevarton, D Olver, I

Permalink

Publisher:: Wiley
Publication Type:: Journal Article
Citation:: European Journal of Cancer Care, 2021, 30, (5)
Issue Date:: 2021-09

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download full textAdobe PDF (458.06 kB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Li, M
dc.contributor.author	Roder, D
dc.contributor.author	D'Onise, K
dc.contributor.author	Walters, D
dc.contributor.author	Farshid, G
dc.contributor.author	Buckley, E
dc.contributor.author	Karapetis, C
dc.contributor.author	Joshi, R
dc.contributor.author	Price, T
dc.contributor.author	Townsend, A
dc.contributor.author	Miller, C
dc.contributor.author	Currow, D https://orcid.org/0000-0003-1988-1250
dc.contributor.author	Powell, K
dc.contributor.author	Buranyi-Trevarton, D
dc.contributor.author	Olver, I
dc.date.accessioned	2021-10-11T05:13:32Z
dc.date.available	2021-03-18
dc.date.available	2021-10-11T05:13:32Z
dc.date.issued	2021-09
dc.identifier.citation	European Journal of Cancer Care, 2021, 30, (5)
dc.identifier.issn	0961-5423
dc.identifier.issn	1365-2354
dc.identifier.uri	http://hdl.handle.net/10453/150994
dc.description.abstract	Objective We investigated treatment and survival by clinical and sociodemographic characteristics for service evaluation using linked data. Method Data on invasive female breast cancers (n = 13,494) from the South Australian Cancer Registry (2000–2014 diagnoses) were linked to hospital inpatient, radiotherapy and universal health insurance data. Treatments ≤12 months from diagnosis and survival were analysed, using adjusted odds ratios (aORs) from logistic regression, and adjusted sub-hazard ratios (aSHRs) from competing risk regression. Results and conclusion Five-year disease-specific survival increased to 91% for 2010–2014. Most women had breast surgery (90%), systemic therapy (72%) and radiotherapy (60%). Less treatment applied for ages 80+ vs <50 years (aOR 0.10, 95% CI 0.05–0.20) and TNM stage IV vs stage I (aOR 0.13, 95% CI 0.08–0.22). Surgical treatment increased during the study period and strongly predicted higher survival. Compared with no surgery, aSHRs were 0.31 (95% CI 0.26–0.36) for women having breast-conserving surgery, 0.49 (95% CI 0.41–0.57) for mastectomy and 0.42 (95% CI 0.33–0.52) when both surgery types were received. Patients aged 80+ years had lower survival and less treatment. More trial evidence is needed to optimise trade-offs between benefits and harms in these older women. Survival differences were not found by residential remoteness and were marginal by socioeconomic status.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	Wiley
dc.relation.ispartof	European Journal of Cancer Care
dc.relation.isbasedon	10.1111/ecc.13451
dc.rights	info:eu-repo/semantics/openAccess
dc.subject	1110 Nursing, 1112 Oncology and Carcinogenesis, 1117 Public Health and Health Services
dc.subject.classification	Oncology & Carcinogenesis
dc.subject.mesh	Aged
dc.subject.mesh	Aged, 80 and over
dc.subject.mesh	Australia
dc.subject.mesh	Breast Neoplasms
dc.subject.mesh	Female
dc.subject.mesh	Humans
dc.subject.mesh	Mastectomy
dc.subject.mesh	Mastectomy, Segmental
dc.subject.mesh	Neoplasm Staging
dc.subject.mesh	Semantic Web
dc.subject.mesh	South Australia
dc.subject.mesh	Humans
dc.subject.mesh	Breast Neoplasms
dc.subject.mesh	Neoplasm Staging
dc.subject.mesh	Mastectomy
dc.subject.mesh	Mastectomy, Segmental
dc.subject.mesh	Aged
dc.subject.mesh	Aged, 80 and over
dc.subject.mesh	Australia
dc.subject.mesh	South Australia
dc.subject.mesh	Female
dc.subject.mesh	Semantic Web
dc.subject.mesh	Aged
dc.subject.mesh	Aged, 80 and over
dc.subject.mesh	Australia
dc.subject.mesh	Breast Neoplasms
dc.subject.mesh	Female
dc.subject.mesh	Humans
dc.subject.mesh	Mastectomy
dc.subject.mesh	Mastectomy, Segmental
dc.subject.mesh	Neoplasm Staging
dc.subject.mesh	Semantic Web
dc.subject.mesh	South Australia
dc.title	Female breast cancer treatment and survival in South Australia: Results from linked health data.
dc.type	Journal Article
utslib.citation.volume	30
utslib.location.activity	England
utslib.for	1110 Nursing
utslib.for	1112 Oncology and Carcinogenesis
utslib.for	1117 Public Health and Health Services
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/IMPACCT
utslib.copyright.status	open_access	*
pubs.consider-herdc	false
dc.date.updated	2021-10-11T05:13:31Z
pubs.issue	5
pubs.publication-status	Published
pubs.volume	30
utslib.citation.issue	5

Abstract:

Objective We investigated treatment and survival by clinical and sociodemographic characteristics for service evaluation using linked data. Method Data on invasive female breast cancers (n = 13,494) from the South Australian Cancer Registry (2000–2014 diagnoses) were linked to hospital inpatient, radiotherapy and universal health insurance data. Treatments ≤12 months from diagnosis and survival were analysed, using adjusted odds ratios (aORs) from logistic regression, and adjusted sub-hazard ratios (aSHRs) from competing risk regression. Results and conclusion Five-year disease-specific survival increased to 91% for 2010–2014. Most women had breast surgery (90%), systemic therapy (72%) and radiotherapy (60%). Less treatment applied for ages 80+ vs <50 years (aOR 0.10, 95% CI 0.05–0.20) and TNM stage IV vs stage I (aOR 0.13, 95% CI 0.08–0.22). Surgical treatment increased during the study period and strongly predicted higher survival. Compared with no surgery, aSHRs were 0.31 (95% CI 0.26–0.36) for women having breast-conserving surgery, 0.49 (95% CI 0.41–0.57) for mastectomy and 0.42 (95% CI 0.33–0.52) when both surgery types were received. Patients aged 80+ years had lower survival and less treatment. More trial evidence is needed to optimise trade-offs between benefits and harms in these older women. Survival differences were not found by residential remoteness and were marginal by socioeconomic status.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/150994